No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.

Details

Ressource 1Download: article.pdf (1037.00 [Ko])
State: Public
Version: author
License: CC BY 4.0
Serval ID
serval:BIB_4A53A3D43CC0
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis.
Journal
BMC research notes
Author(s)
Claude F., Rochat I., Hafen G.M.
ISSN
1756-0500 (Electronic)
ISSN-L
1756-0500
Publication state
Published
Issued date
03/2019
Volume
12
Number
1
Pages
115
Language
english
Abstract
Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfections, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months’ period.
Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or even inferior to figures published in the literature.
Pubmed
Create date
24/09/2019 14:12
Last modification date
01/10/2019 7:08
Usage data